Significance of additional chromosomal abnormalities (ACAs) in Egyptian chronic myeloid leukemia patients / Sarah Khaled Ibrahim Mohammed Abdullah ; Supervised Magda Mahmoud Assem , Yasser H. Elnahass

By:

Sarah Khaled Ibrahim Mohammed Abdullah

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Sarah Khaled Ibrahim Mohammed Abdullah , 2019Description: 192 P. : charts , facsimiles ; 25cmOther title:

دراسة أهمية الاضطرابات الكروموسومية الاضافية في المرضى المصريين المصابين بسرطان الدم الميلودي المزمن [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) Summary: Background : The emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) signifies clonal evolution associated with disease progression to accelerated/blastic phase and reflects the genetic instability of CML The early identification of (ACAs) in Ph+ metaphases at diagnosis by chromosome banding analysis is of clinical and biological importance. Aim of work: The aim of the current study was to evaluate the frequency of additional chromosomal abnormalities (ACAs) at time of diagnosis and during therapy in CML patients presenting with chronic phase or advanced disease (accelerated or blast phase) and to study the impact of (ACAs) as regards patients response to tyrosine kinase inhibitor (TKI) therapy and overall (OS) and event free survival (EFS)

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2019.Sa.S (Browse shelf(Opens below))		Not for loan	01010110078661000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2019.Sa.S (Browse shelf(Opens below))	78661.CD	Not for loan	01020110078661000

Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)

Previous	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	Next
Previous	Cai01.19.04.Ph.D.2019.Mo.R Role of sentinel lymph node biopsy in staging of early endometrial cancer /	Cai01.19.04.Ph.D.2019.Mo.T Treatment-free remission after stopping tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase achieving major molecular response /	Cai01.19.04.Ph.D.2019.Mo.T Treatment-free remission after stopping tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase achieving major molecular response /	Cai01.19.04.Ph.D.2019.Sa.S Significance of additional chromosomal abnormalities (ACAs) in Egyptian chronic myeloid leukemia patients /	Cai01.19.04.Ph.D.2019.Sa.S Significance of additional chromosomal abnormalities (ACAs) in Egyptian chronic myeloid leukemia patients /	Cai01.19.04.Ph.D.2019.Sh.P Patterns and predictors of failure and disease recurrence after cytoreductive surgery and HIPEC for colorectal carcinoma /	Cai01.19.04.Ph.D.2019.Sh.P Patterns and predictors of failure and disease recurrence after cytoreductive surgery and HIPEC for colorectal carcinoma /	Next

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical)

Background : The emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) signifies clonal evolution associated with disease progression to accelerated/blastic phase and reflects the genetic instability of CML The early identification of (ACAs) in Ph+ metaphases at diagnosis by chromosome banding analysis is of clinical and biological importance. Aim of work: The aim of the current study was to evaluate the frequency of additional chromosomal abnormalities (ACAs) at time of diagnosis and during therapy in CML patients presenting with chronic phase or advanced disease (accelerated or blast phase) and to study the impact of (ACAs) as regards patients response to tyrosine kinase inhibitor (TKI) therapy and overall (OS) and event free survival (EFS)

Issued also as CD

There are no comments on this title.

to post a comment.